PALI
Palisade Bio, Inc. NASDAQ$2.13
Mkt Cap $356.6M
52w Low $0.53
68.7% of range
52w High $2.86
50d MA $1.96
200d MA $1.61
P/E (TTM)
-6.6x
EV/EBITDA
0.1x
P/B
0.9x
Debt/Equity
0.0x
ROE
-13.0%
P/FCF
-12.1x
RSI (14)
—
ATR (14)
—
Beta
1.47
50d MA
$1.96
200d MA
$1.61
Avg Volume
4.1M
About
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enz…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.02 | -0.04 | -100.0% | 1.91 | -0.5% | +4.7% | +4.7% | +2.6% | +4.7% | -6.8% | — |
| Nov 10, 2025 | AMC | -0.32 | -0.38 | -18.8% | 1.77 | -0.6% | +2.8% | +15.3% | +5.6% | +20.9% | +16.9% | — |
| Aug 11, 2025 | AMC | -0.48 | -0.58 | -20.8% | 0.74 | -7.8% | +1.4% | +9.6% | +10.1% | +8.2% | +8.2% | — |
| May 12, 2025 | AMC | -0.84 | -0.47 | +44.0% | 0.77 | +4.0% | -5.1% | -9.2% | -11.6% | -10.7% | -10.5% | — |
| Mar 24, 2025 | AMC | -1.99 | -0.69 | +65.3% | 0.70 | +2.6% | -1.6% | -0.9% | -1.6% | -1.8% | -2.9% | — |
| Nov 12, 2024 | AMC | -3.35 | -2.32 | +30.7% | 2.38 | +3.4% | -7.6% | +10.1% | +5.9% | +0.4% | +2.1% | — |
| Aug 12, 2024 | AMC | -2.93 | -3.32 | -13.3% | 3.66 | -0.3% | +1.1% | -2.2% | +1.4% | +7.7% | -1.4% | — |
| May 13, 2024 | AMC | -4.80 | -4.59 | +4.4% | 6.22 | -3.5% | +0.3% | +2.6% | +3.9% | +2.3% | -5.9% | — |
| Mar 26, 2024 | AMC | -5.17 | -3.75 | +27.5% | 5.59 | +2.0% | +6.1% | +7.2% | +4.7% | +2.7% | +4.5% | — |
| Nov 9, 2023 | AMC | -0.39 | -7.35 | -1784.6% | 7.80 | +2.9% | +1.9% | +1.3% | +0.0% | +1.9% | +0.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 | Brookline Capital | Maintains | Buy → Buy | — | $0.77 | $0.80 | +4.0% | -5.1% | -9.2% | -11.6% | -10.7% | -10.5% |
| Nov 13 | Maxim Group | Maintains | Buy → Buy | — | $2.38 | $2.46 | +3.4% | -7.6% | +10.1% | +5.9% | +0.4% | +2.1% |
| May 1 | Maxim Group | Maintains | Buy → Buy | — | $6.03 | $7.95 | +31.8% | +17.4% | +20.9% | +28.4% | +40.3% | +31.0% |
| Apr 16 | Maxim Group | Maintains | Buy → Buy | — | $4.16 | $8.75 | +110.3% | +42.5% | +58.7% | +21.9% | +13.2% | +18.5% |
| Nov 17 | Maxim Group | Upgrade | Hold → Buy | — | $7.85 | $8.25 | +5.1% | +15.5% | +14.6% | +12.7% | +10.7% | +11.8% |
| May 16 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $23.85 | $23.70 | -0.6% | +0.6% | +1.3% | -1.3% | -6.3% | -7.5% |
| Mar 30 | Maxim Group | Upgrade | Hold → Buy | — | $25.20 | $29.40 | +16.7% | +57.7% | +109.5% | +34.5% | +20.8% | +29.8% |
| Aug 19 | Maxim Group | Downgrade | Buy → Hold | — | $123.08 | $126.75 | +3.0% | +9.7% | -1.8% | +2.1% | +6.6% | +14.4% |
| Feb 2 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $922.50 | $960.00 | +4.1% | -17.1% | -31.5% | -24.8% | -22.0% | -15.4% |
| Aug 31 | Maxim Group | Maintains | Buy → Buy | — | $2047.50 | $2317.50 | +13.2% | +2.9% | -2.2% | +1.1% | +0.0% | +5.9% |
Recent Filings
Data updated apr 26, 2026 6:33pm
· Source: massive.com